Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 4c; Boosts FY13 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jefferies Raises Numbers on Myriad Genetics (MYGN)
November 6, 2012 12:54 PM ESTJefferies maintained a Buy rating on Myriad Genetics (NASDAQ: MYGN) and raised its price target to $33.00 (from $31.00). Myriad recently reported earnings that were ahead of consensus, and as a result analysts raised EPS estimates on the diagnostics company.
"We expect... More
